Jose L Contreras-Vidal, Ph.D.’s Post

🔬💡 Translational research is like a relay race, with crucial handoffs from the lab to patient care. Our Miami Clinical and Translational Science Institute is here to support these handoffs, advancing discoveries toward real-world impact. Learn how the team, led by co-directors Dr. Kobetz and Dr. Carrasquillo, are helping #TeamScience thrive. 🌱🤝 https://loom.ly/h-8BO4o

🚀 Wyss Center invests CHF 750,000 in dEEGtal The Wyss Center for Bio and Neuroengineering supports dEEGtal Insight SA, an innovative spin-off from Université de Genève and HUG - Hôpitaux Universitaires de Genève. Using AI-powered technology, dEEGtal Insight simplifies EEG analysis and enhances epilepsy detection for faster, more accurate diagnoses. Wyss Center Director Erwin Böttinger states: "This partnership underscores our commitment to impactful healthcare innovation." Congratulations Eric Ménétré, Stefano Gallotto & Prof. Margitta Seeck https://lnkd.in/e3RCM3it #HealthcareInnovation #EpilepsyDiagnosis #AIinMedicine

The Revolution in Quantum Sensing: Pioneering Global Research for Biomedical Breakthroughs! I had the privilege of participating in an enlightening discussion on our research project on quantum sensing technologies and their potential to transform biomedical and clinical applications. It was such a fruitfully discussion during my US-visit. This transformative field holds immense potential to redefine the way we approach disease prevention, monitoring, and diagnosis through affordable and portable solutions. Pioneering Research Discussion on Disease detection, Prevention and Diagnosis. We had an esteem research project discussion with Ravi Puvvala, Juri Baruah, Subu Gupta, and Tushar Ravuri. Being a part of this groundbreaking initiative is an honor, and I am excited to contribute to its vision of reshaping global healthcare through the integration of quantum science and biomedical innovation. Here’s to creating a future where advanced diagnostics and precision medicine become more accessible and impactful! #QuantumSensing #GlobalInnovation #BiomedicalResearch #PrecisionDiagnostics #QuantumForHealth #RevolutionizingHealthcare

✨ Thanks to MassDevice and Sean Whooley for an informative piece detailing our work with brain-computer interface (BCI) technology.     The article covered our recent announcement of a third successful implant of our investigational ARC-BCI™ Therapy to restore thought-driven movement after spinal cord injury (SCI).     This milestone event, which involved the use of our investigational ARC-BCI System to restore lower limb mobility after SCI, is part of an ongoing clinical feasibility study supported by grants from the Christopher & Dana Reeve Foundation and the European Innovation Council and SMEs Executive Agency (EISMEA) and in coordination with our research collaborators, neuroscientists Professor G. Courtine and Dr. Jocelyne Bloch of .NeuroRestore, and Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA-Clinatec).    In the rapidly evolving field of BCI technology, education is key to keeping the public updated. We appreciate Sean’s informed reporting and MassDevice’s commitment to providing accurate information and thoughtful context about breakthroughs in #BCI. 🙏    🔗 Link to article in comments    #EmpoweringMovement #SCI #BCI     Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.    

Exploring the 𝐃𝐲𝐧𝐚𝐦𝐢𝐜 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐚𝐧𝐝 𝐁𝐢𝐨𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 has been one of the key focus areas for Frontiers Health over the last several conference editions. As we venture into the frontiers of #lifesciences, leveraging partnerships, knowledge, and skill exchange, I have found the journey so far extremely fascinating. With Eino Solje, we examined the ongoing revolutions in the field of #neurodegenerativediseases. We discussed #CardioMetabolicDiseases, focusing on precision and prevention at scale, in a panel moderated by Charles Alessi. Alex Zhavoronkov from Insilico Medicine explored #generativeAI applications in therapeutic target discovery, small molecule generation, clinical trial prediction, and aging research. Additionally, we delved into 'Designing DNA to Discover New Medicines' with an insightful keynote curated by Sidhyansh Saxena from Ginkgo Bioworks, Inc., a pioneering #biotech company renowned for its work in #syntheticbiology (#synbio). Moreover, we immersed our audience in the latest advancements in #DecentralizedScience, #clinicalresearch, and #translationalmedicine. With the invaluable contribution of Nana Bit-Avragim (she/her), I have endeavored to condense all this rich content into a piece available here: https://lnkd.in/e2fBFken Want to keep exploring the frontiers of science and biomedical innovations? Join us at FH24 and secure your seat now while the super early bird offer is still available! 👉 🎟 https://lnkd.in/dwzNinp4 Roberto Ascione Elena Pirofalo Kristin Milburn Antonietta Pannella Giovanna D'Urso

📢 Upcoming Lecture Announcement: Amblyopia and its Relationship to Myopia Management Using DIMS Join us for an enlightening presentation by Professor Emeritus Robert Francis Hess, Director of McGill Vision Research, as he explores the relationship between amblyopia and the management of myopia using DIMS lenses. The DIMS lens, designed to slow the progression of myopia by inducing peripheral defocus, raises two important questions: The DIMS lens is designed to reduce the progression of myopia by producing a chronic defocus in the periphery. Two questions arise, firstly, could this in itself produce a peripheral amblyopia in a young myope and secondly, are there any contraindications to the management of myopia in a young person who is concurrently undergoing patching therapy for amblyopia? The interaction of these two conditions will be assessed based on current laboratory research. Webinar Details: 🗓️ Date: Thursday 24th October 2024 @ 6.30 CEST ⚠️ Limited spaces available – reserve your spot now! This lecture is proudly sponsored by Hoya Vision. Don't miss this opportunity to dive into cutting-edge vision research!

🎉 Exciting News! 🎉 I'm thrilled to share that our research paper, "Enhancing Liver Cirrhosis Diagnosis: A Comparative Analysis of XGBoost, SVM, and Random Forest Classifiers for Optimal Predictive Analysis," has been accepted at the prestigious 4th International Conference on Computational Methods in Science and Technology (ICCMST) 2024! Cirrhosis of the liver, an irreversible liver disease, replaces healthy tissue with scar tissue and impairs liver function. Drawing data from a long-term Mayo Clinic investigation on primary biliary cirrhosis, our study evaluates the efficacy of XGBoost, SVM, and RandomForest classifiers. This breakthrough research underscores the critical significance of selecting the appropriate predictive model in medical prognosis. These findings not only advance healthcare analytics but also offer essential guidance for refining predictive models, ultimately leading to improved health outcomes. 🌟 I had the wonderful opportunity to present our findings and insights at the conference on 2nd May 2024. It was an enriching experience to share our work with esteemed faculties, and overall, it was truly remarkable. I extend my heartfelt thanks to my dedicated teammate, AVNI GUPTA, and my mentor, Dr. Sanchali Das Ma'am, for their invaluable support and guidance throughout this research journey. Looking forward to more research opportunities and contributing further to the field! 🚀 #Research #DataScience #MachineLearning #ICCMST2024  

In case you missed last week Morgan Stanley shared their thoughts and research on the market for commercialization of Brain Computer Interfaces (#BCI). 🌍The potential of BCIs is no longer a distant vision- it's happening now. After decades of research in academia we are on the breakthrough of profoundly improving lives of millions suffering from neurological disorders like #ALS, #Stroke, #spinalcordinjuries and beyond. Morgan Stanley estimates a $400 billion total addressable market (TAM) in the U.S. alone. BCI's are set to transform healthcare. But what does it really mean? 👩🏾🤝👨🏻For Patients and Families: Imagine giving people who are locked in by disease like ALS a way to communicate with the world again or helping stroke survivors regain motor function. I lost my father-in-law to ALS at the end of June, and he was no longer able to communicate with my kids to say his final goodbye as we lived states away, and their only communication was via phone. For him and my kids BCI means a restored independence and improved quality of life for their loved ones, and the ability to communicate. The innovations in BCI will redefine what is possible in neurorehabilitation, providing hope for millions affected by conditions that have long been considered irreversible. 📈 Scaling and Investment Opportunities: In the next 5 years as we move towards commercialization, the growth potential is immense. Initial revenue estimates suggest the BCIs could generate over $1Billion in the first phase. At Precision Neuroscience we believe in the first stage there is a $2.5-$3 billion per year opportunity in the first stage. 💼 The Bottom Line: BCIs are not just an innovation, they are a medical necessity for millions of patients to reconnect with the world, their environment, and their loved ones. A way to give people their voices back, ability to return to work, and to restore their independence. BCIs are set to impact the future of healthcare and is the next big MedTech revolution🧠🚀 #BCI #healthcareinnovation #MedTech #Neuroscience #Patientcare #InvestInTheFuture

😎 Looking forward to soon meeting and exchanging ideas with all attendees at 𝗜𝗖𝗡𝗥 𝟮𝟬𝟮𝟰 (https://lnkd.in/d35ge6Fu) in La Granja, Spain from November 5th-8th 2024. Together with my colleague José López Sánchez, I will co-chair the special session 𝗥𝗥𝟬𝟱. 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗻𝗴 𝗛𝘂𝗺𝗮𝗻 𝗙𝗮𝗰𝘁𝗼𝗿𝘀, 𝗜𝗻𝘁𝗲𝗻𝘀𝗶𝘁𝘆 𝗧𝗿𝗮𝗶𝗻𝗶𝗻𝗴 𝗥𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀, 𝗮𝗻𝗱 𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀: 𝗔𝗻 𝗜𝗻𝘁𝗲𝗿𝗱𝗶𝘀𝗰𝗶𝗽𝗹𝗶𝗻𝗮𝗿𝘆 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝘁𝗼 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗮𝗻𝗱 𝗥𝗲𝗵𝗮𝗯𝗶𝗹𝗶𝘁𝗮𝘁𝗶𝗼𝗻 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀. 🔊 In our special session, we will dive into various topics: - The feasibility of deploying soft-exoskeleton gait training with the Myosuit from MyoSwiss AG from the inpatient into the home-setting, by Liliana Paredes (presenter) from the Biomedical Data Science Lab at ETH, Carmel Tulen and colleagues from the Rehaklinik Zihlschlacht. - A systematic review challenging the belief that gait recovery during the chronic phase of stroke is not possible, by José López Sánchez (presenter) and colleagues, CEN - Centro Europeo de Neurociencias CENNEURO. - Following that, CMO Daniel Zutter of VAMED Schweiz will present the history and future vision of assessments in Neurorehabilitation. While extensive measurements in the field are common, they often strain resources without proving their benefit, and Daniel calls for clearer, distinct measurement tools for different stakeholders. What should we measure? AI also needs good data. - Finally, Miklovana Tuci from the Biomedical Data Science Lab at ETH will present the concept of digital twins for spinal cord injury patients, enabling simulation of expected recovery through standard rehabilitation protocols. 🙏 These presentations underscore the importance of innovative technologies and interdisciplinary approaches in advancing digital health and rehabilitation. We will highlight challenges, opportunities, and promising avenues for improving patient outcomes in neurological and SCI rehabilitation. We can't wait to see you there! 🚀 #rehabtech #neurorehabilitation #ICNR2024 #feasibity #assessments #chronicstroke #digitaltwins

Don't miss GCLS Faculty member 'Agingdoc,' Dr. David Barzilai, as he shares insights on the latest advancements in longevity science in his latest interview!